--- title: "Innovent Biologics falls 5%" type: "News" locale: "en" url: "https://longbridge.com/en/news/306200629.md" description: "Innovent Biologics fell 5.32% to HK$80.90. Down 6.31% over ten sessions and up 6.10% YTD." datetime: "2026-11-20T01:44:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306200629.md) - [en](https://longbridge.com/en/news/306200629.md) - [zh-HK](https://longbridge.com/zh-HK/news/306200629.md) generator: "portal-rs" --- # Innovent Biologics falls 5% Innovent Biologics (1801.HK) fell more than **5%** in Hong Kong trading to **HK$80.90**. The stock is down 6.31% over the past ten sessions and up 6.10% year to date. It sits 28.22% below its 52-week high of HK$112.70. Volume was 2.10 times its average. The Hang Seng Index is down 4.61% over the past five sessions and down 12.03% year to date. The biotechnology industry index fell 3.4% over the same period. Based on public media reports. AI-generated; not investment advice. ### Related Stocks - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) ## Related News & Research - [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md) - [Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer Treatment](https://longbridge.com/en/news/305586235.md) - [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO Ophthalmology R&D](https://longbridge.com/en/news/305767362.md) - [Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List](https://longbridge.com/en/news/305522173.md) - [Innovent Biologics reports 1H results](https://longbridge.com/en/news/296950734.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**